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Numerous articles, including two case-control
studies, have been published documenting a causal
association between the use of oral contraceptives
and benign liver tumours, variously described as
adenomas or focal nodular hyperplasia (Baum et
al., 1973; Edmondson et al., 1976; Rooks et al.,
1979). A definite relationship between oral
contraceptive use and malignant liver tumours has
not been established, but experimental animal
studies have shown that oral contraceptives can
cause hepatomas in mice and are effective
promotors of hepatocarcinogenesis in
diethylnitrosamine-primed rats (International
Agency for Research on Cancer, 1974; Yager &
Yager, 1980; Wanless & Medline, 1982), and at
least 10 case reports of hepatocellular carcinoma
arising in women taking oral contraceptives have
been published (Meyer et al., 1974; Thalissinos et
al., 1974; Davis et al., 1975; Glasberg &
Rosenbaum, 1976; Mays et al., 1976; O'Sullivan &
Rosswick, 1976; Pryor et al., 1977; Trias et al.,
1978; Tesluk & Lawrie, 1981). We now report 11
further cases of malignant liver tumours in young
women and document a statistically significant
association between these tumours and use of oral
contraceptives.
All new cases of liver cancer in U.S.-born women
aged 18-39 years occurring during 1975-1980 were
obtained from the population-based cancer registry
for Los Angeles County (Mack, 1977). Of the 12
such cases we were able to obtain completed
interviews from the patients or their relatives or
family physician in 11 instances. The husband of
one case who had died refused to be interviewed
and refused us permission to contact other family
members. Two controls were sought for each of the
patients by a systematic door-to-door survey in the
neighbourhood in which the patient lived at
diagnosis. This neighbourhood algorithm provides a
close match on socio-economic and ethnic status.
The patient and her control had to be of the same
ethnic group (white, black), with birth dates no
more than 5 years apart, and the control -at
interview had to be at least as old as the patient
was at time of diagnosis of liver cancer (the actual
birthdates of the controls were on average 9
months earlier than that of cases). Nine of the cases
were white women and 2 were black. An average of
27 households (range, 14-53) had to be surveyed to
find 2 matched controls who were willing to be
interviewed. Of the 297 total houses surveyed we
were still not able to obtain a complete census,
after 3 visits and leaving 2 letters, in 13 (4.3%), so
that a potential control may have been missed in
these households. Four identified matched controls
refused to be interviewed.
All interviews were conducted by telephone using
a rigidly structured questionnaire. Information thus
obtained included reproductive, menstrual and
contraceptive history; hormone, alcohol and drug
use; and industrial exposure to possible
hepatotoxins. Each control was given a "pseudo-
diagnosis" date which was the date on which she
would have been the exact age her matched case
was at diagnosis. Data were recorded up to the
diagnosis (pseudo-diagnosis) date. We were only
able to interview 3 of the cases in person (Case nos.
4, 5 and 8 in Table I). When we were unable to
interview the case we attempted to interview in
decreasing order of preference: her husband (Case
nos. 1, 3 and 6), mother (Case nos. 7, 9 and 11),
and father (Case no. 2). The family physician of the
remaining patient (Case no. 10) refused us
permission to interview the family, but he knew the
patient well and we interviewed him about her.
Selected clinical and histopathological data on
the 11 cases of liver cancer are presented in Table I.
All the cases have died. Six of the cases and 9 of
the controls were single. Data on the oral
contraceptive use of the case and her two controls
are also shown in Table I.
Ten of the cases had used oral contracptives for
periods ranging from 6 to 168 months. One
additional patient (Case no. 7) had received
multiple "hormone" shots of undetermined type,
for regulation of menstrual periods during the 9
months preceding diagnosis. Six of the 11 patients
(including Case nos. 4 and 7) were taking hormones
at the time of diagnosis. The average duration of
use in the 11 cases was 64.7 months and in the
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Table I Selected clinical and laboratory data on 11 cases of liver cancer in women 18-
39 years of age, Los Angeles County, 1975-1980.
Year Months oforal
Case of contraceptive use:
no. Age diagnosis Histopathology Case Controls
1 37 1975 Giant cell carcinoma 40 0, 40
(autopsy)
2 18 1977 Microtrabecular hepatocellular
carcinoma 37 0, 3
3 32 1977 Hepatocellular carcinoma 132 19, 46
4 20 1977 Fibrolamellar hepatocellular
carcinoma 6 0, 0
5 22 1977 Fibrolamellar hepatocellular
carcinoma 15 0, 12
6 39 1977 Hepatocellular carcinoma 120 0, 72
7 21 1978 Well-differentiated
'hepatocellular carcinoma 0* 0, 0
8 26 1978 Sclerosing duct forming carcinoma 72 73, 54
9 35 1979 Papillary squamous cell carcinoma 168 42,24
10 35 1980 Fibrolamellar hepatocellular
carcinoma 61 0, 83
11 21 1980 Hepatocellular carcinoma, benign
adenoma, and focal nodular
hyperplasia 60 71, 58
*Nine months ofhormone injections (see text).
controls was 27.1 months-this difference is
statistically highly significant (1-sided P<0.005: test
for trend retaining the matching triplets (Breslow &
Day, 1981)). This difference was apparent for both
single cases and controls, and for married cases and
controls.
Histopathological material from all of the cases
was reviewed by two pathologists (HAE and RLP).
Three of the cases (nos. 4, 5 and 10) had typical
fibrolamellar carcinomas and one (Case no. 2) a
typical microtrabecullar carcinoma. One other
(Case no. 7) was a typical well-differentiated
hepatocellular carcinoma. In 3 additional cases
(Case nos. 3, 6 and 11), the carcinoma was more
undifferentiated, but in each case some trabecullar
pattern was evident, consistent with the hepatic
origin of these neoplasms. In Case no. 11 the
hepatocellular carcinoma occurred alongside a
benign liver adenoma, typical of the type associated
with oral contraceptives (Figure 1): the same liver
also contained a classic lesion of focal nodular
hyperplasia.
The remaining 3 cases (Case nos. 1, 8 and 9) had
distinctly unusual liver neoplasms. Case no. 1 had a
highly malignant giant cell carcinoma. The
neoplasm in Case no. 8 was a sclerosing duct
forming carcinoma with features of both
cholangiocarcinoma and hepatocellular carcinoma.
Case no. 9 was a papillary carcinoma, mostly
squamous cell, of the type that could arise in a cyst.
This latter tumour, probably the most atypical liver
carcinoma of the 11 cases, occurred in a woman
who had used oral contraceptives for 168 months.
These latter 3 unusual cases all came to autopsy, at
which no other primary neoplasms were found.
None of the cases or controls reported a prior
history of hepatitis or jaundice. None of the 4 cases
tested were HBsAG positive. None of the cases
reported job related exposure to any known
hepatotoxin such as vinyl chloride. There was no
difference in the frequency of alcohol consumption
between cases and controls: 7 of the cases
consumed no more than an occasional drink.
The clinical, pathological and epidemiological
data presented above strongly suggest that long-
term oral contraceptive use may cause malignant
liver tumours. In one case, the malignant tumour
appeared to develop in association with a typical
benign liver adenoma-this strongly suggests a
common aetiology. No particular oral contraceptive
formulation appeared to be responsible for this
association. In none of the women was thereLIVER CANCER AND ORAL CONTRACEPTIVES 439
Figure 1 Pigmented hepatocytes of benign adenoma are shown on the lower left, and just above is an
intravascular growth of hepatocellular carcinoma. An intravascular solitary trabecula of the pigmented
adenoma is noted in the left center (arrow).
evidence of exposure to other potential causes of
liver cell carcinoma including vinyl chloride,
hepatitis B virus, or excessive alcohol intake.
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